[
  {
    "question": "Patient on anti-TB agents developed seizures, which of the following agents can cause it?",
    "option_a": "INH",
    "option_b": "Ethambutol",
    "option_c": "Pyrazinamide",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Anti\u2010tuberculosis therapy involves several drugs with distinct side effect profiles. Isoniazid (INH) is well known to cause neurotoxicity, including seizures and peripheral neuropathy, primarily through interference with vitamin B6 (pyridoxine) metabolism. INH can induce seizures by depleting pyridoxine, an essential cofactor in the synthesis of gamma\u2010aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS. Reduced GABA levels lead to neuronal hyperexcitability. This mechanism is especially evident in overdose situations but may also occur in susceptible individuals on therapeutic doses. In a patient on anti-TB agents who develops seizures, the timing and medication history are critical clues. Seizures secondary to INH toxicity may present acutely, and the clinical picture is distinguished from other causes by the association with INH use and response to pyridoxine administration. Diagnosis is clinical, supported by the patient\u2019s medication history. Laboratory evaluation may include measurement of INH levels in overdose scenarios. Differential diagnoses include electrolyte disturbances, other drug toxicities, and primary seizure disorders. Neuroimaging and EEG are used to exclude alternative intracranial pathologies. First-line management is the administration of pyridoxine (vitamin B6) \u2013 often given in doses equivalent to the ingested amount of INH in overdose situations. Supportive care and anticonvulsants (e.g., benzodiazepines) may be required to control seizures acutely. Current guidelines recommend routine pyridoxine supplementation in patients at risk, including special considerations during pregnancy and lactation, as pyridoxine is safe in these populations. Option A (INH) is correct because it is the agent known to cause seizures via pyridoxine depletion. Option B (Ethambutol) is more associated with optic neuritis, and Option C (Pyrazinamide) typically causes hyperuricemia; neither is linked to seizure activity. \u2022 Always co-administer pyridoxine with INH in high-risk patients. \u2022 In INH overdose, immediate pyridoxine administration can be life-saving. \u2022 A detailed medication history is crucial when evaluating new-onset seizures in TB patients. Recent studies and clinical guidelines continue to underscore the importance of vitamin B6 supplementation during INH therapy. Newer research reinforces the role of pyridoxine in mitigating neurotoxic effects, and current recommendations remain unchanged even in special populations such as pregnant or lactating women.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has NPH and abdominal tb ??",
    "option_a": "(INH) is correct because it is the agent known to cause seizures via pyridoxine depletion. Option B (Ethambutol) is more associated with optic neuritis, and Option C (Pyrazinamide) typically causes hyperuricemia; neither is linked to seizure activity.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Anti\u2010tuberculosis therapy involves several drugs with distinct side effect profiles. Isoniazid (INH) is well known to cause neurotoxicity, including seizures and peripheral neuropathy, primarily through interference with vitamin B6 (pyridoxine) metabolism. INH can induce seizures by depleting pyridoxine, an essential cofactor in the synthesis of gamma\u2010aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS. Reduced GABA levels lead to neuronal hyperexcitability. This mechanism is especially evident in overdose situations but may also occur in susceptible individuals on therapeutic doses. In a patient on anti-TB agents who develops seizures, the timing and medication history are critical clues. Seizures secondary to INH toxicity may present acutely, and the clinical picture is distinguished from other causes by the association with INH use and response to pyridoxine administration. Diagnosis is clinical, supported by the patient\u2019s medication history. Laboratory evaluation may include measurement of INH levels in overdose scenarios. Differential diagnoses include electrolyte disturbances, other drug toxicities, and primary seizure disorders. Neuroimaging and EEG are used to exclude alternative intracranial pathologies. First-line management is the administration of pyridoxine (vitamin B6) \u2013 often given in doses equivalent to the ingested amount of INH in overdose situations. Supportive care and anticonvulsants (e.g., benzodiazepines) may be required to control seizures acutely. Current guidelines recommend routine pyridoxine supplementation in patients at risk, including special considerations during pregnancy and lactation, as pyridoxine is safe in these populations. Option A (INH) is correct because it is the agent known to cause seizures via pyridoxine depletion. Option B (Ethambutol) is more associated with optic neuritis, and Option C (Pyrazinamide) typically causes hyperuricemia; neither is linked to seizure activity. \u2022 Always co-administer pyridoxine with INH in high-risk patients. \u2022 In INH overdose, immediate pyridoxine administration can be life-saving. \u2022 A detailed medication history is crucial when evaluating new-onset seizures in TB patients. Recent studies and clinical guidelines continue to underscore the importance of vitamin B6 supplementation during INH therapy. Newer research reinforces the role of pyridoxine in mitigating neurotoxic effects, and current recommendations remain unchanged even in special populations such as pregnant or lactating women.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient was having herpes zoster infection developed cognitive impairment, what is the most likely diagnosis?",
    "option_a": "HZ encephalitis",
    "option_b": "Drug induced",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Herpes zoster is the reactivation of the varicella zoster virus, which can, in some cases, spread to the central nervous system resulting in encephalitis. When a patient with herpes zoster develops cognitive impairment, the most direct and plausible explanation is the development of herpes zoster encephalitis. In herpes zoster encephalitis, reactivated varicella zoster virus travels from the dorsal root or cranial nerve ganglia to the brain parenchyma. This causes an inflammatory response resulting in neuronal injury and the subsequent clinical picture of encephalitis, which includes cognitive dysfunction, confusion, and altered mental status. Patients presenting with herpes zoster, particularly those who are older or immunocompromised, are at risk for complications including CNS involvement. Cognitive impairment in such cases should alert clinicians to the possibility of encephalitis rather than attributing symptoms to drug side effects, which is less typical in this context. The differential diagnosis includes herpes zoster encephalitis, herpes simplex encephalitis, and drug-induced cognitive impairment. A lumbar puncture with CSF analysis and PCR testing for VZV, along with neuroimaging (MRI), are key to confirming the diagnosis of HZ encephalitis. The mainstay of treatment for HZ encephalitis is prompt antiviral therapy, typically intravenous acyclovir administered for 10-14 days. In pregnant and lactating women, acyclovir is also the first-line treatment; however, clinicians must carefully balance maternal benefits with fetal and neonatal safety, following current guidelines that support its use after thorough risk assessment. Option A (HZ encephalitis) aligns directly with the clinical scenario of cognitive impairment following herpes zoster infection. Option B (Drug induced) is less compatible with the sequence of events and typical pathophysiology seen in herpes zoster cases, making it an unlikely cause of cognitive impairment. Early recognition of CNS involvement in patients with herpes zoster is crucial. Encephalitis should be suspected in any patient with herpes zoster who develops altered mental status. Timely initiation of antiviral therapy is key to improving outcomes. Pregnancy and lactation do not preclude the use of acyclovir, but require careful monitoring. Recent evidence supports the use of PCR testing for VZV in CSF to rapidly diagnose herpes zoster encephalitis. Current guidelines from neurology and infectious disease societies endorse early antiviral therapy (with acyclovir) to mitigate the risk of long-term neurologic sequelae, and these recommendations are applicable to special populations such as pregnant and lactating women with appropriate adjustments.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "In neurosyphilis, which of the following can be associated?",
    "option_a": "Hypochromatic macules",
    "option_b": "Erythema nodosum",
    "option_c": "Enlarged",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurosyphilis refers to the infection of the central nervous system by Treponema pallidum. It can present in a variety of ways\u2014ranging from asymptomatic CSF changes to major clinical syndromes like meningovascular syphilis, general paresis, or tabes dorsalis. While many of its systemic and dermatologic manifestations are more typical of secondary syphilis, neurosyphilis is classically identified by its neurological symptoms and supportive imaging or CSF findings. After the initial infection, spirochetes can invade and persist in the CNS, leading to chronic inflammation and subsequent degenerative changes. In parenchymatous neurosyphilis, inflammatory damage can cause atrophy. Such atrophic changes may result in secondary imaging findings, for example, enlarged cerebral ventricles or cisternal spaces due to loss of brain parenchyma. Patients with neurosyphilis may present with cognitive decline, motor and gait disturbances, sensory abnormalities, and pupil abnormalities (e.g., Argyll Robertson pupils). Abnormal neuroimaging, when present, might show enlarged ventricular or cisternal spaces as a result of brain atrophy, which helps correlate the clinical picture with disease progression. Evaluation combines neurological examination, serologic testing (e.g., RPR, FTA-ABS), and CSF studies (VDRL, cell count, protein) to support the diagnosis. Neuroimaging may reveal indirect signs such as atrophy (for example, enlarged ventricles) in more chronic cases. The treatment of neurosyphilis remains high-dose intravenous aqueous crystalline penicillin G for 10\u201314 days as per current guidelines. In pregnant patients, penicillin remains the only recommended therapy given its ability to cross the placenta and effectively treat both the mother and fetus; lactating women can safely receive penicillin while continuing breastfeeding under appropriate clinical supervision. Follow\u2010up CSF examinations are advised to ensure treatment response. Option A (Hypochromatic macules) may be seen in secondary syphilis as part of mucocutaneous manifestations rather than neurosyphilis. Option B (Erythema nodosum) is more associated with conditions like sarcoidosis or TB rather than syphilis. Option C (Enlarged) is presumed to refer to neuroimaging findings \u2014 such as enlarged ventricles or cisterns secondary to cerebral atrophy seen in parenchymatous neurosyphilis. Option D is incomplete. Thus, within this context, Option C is most consistent with a recognized association in neurosyphilis. It is crucial to consider neurosyphilis in patients with unexplained neurological and neuropsychiatric symptoms, even in the absence of overt dermatologic signs. Age, risk factors, and a history of untreated syphilis elevate the suspicion. Neuroimaging may provide supportive evidence in the late stages, particularly when cerebral atrophy leads to secondary enlargements of CSF spaces. Recent guidelines from the CDC reinforce the use of intravenous penicillin G as the standard treatment for neurosyphilis. Continuous review of CSF parameters post-treatment is recommended. Among vulnerable populations\u2014including pregnant and lactating women\u2014penicillin remains safe and effective, underscoring its importance as the treatment of choice.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of HIV vacuolar myelopathy (diagnosis)",
    "option_a": "nalysis highlights that common differentials (e.g., vitamin B12 deficiency, HTLV",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuro-infectious",
    "explanation": "HIV-associated vacuolar myelopathy (HIV-VM) is a chronic, progressive degeneration of the spinal cord seen in advanced HIV infection. It is characterized by spastic paraparesis and often affects the dorsal and lateral columns. The diagnosis is one of exclusion after ruling out other causes of myelopathy. The underlying mechanism is thought to involve direct or indirect effects of HIV proteins, possibly mediated via toxic cytokines, leading to vacuolation and demyelination within the spinal cord white matter. Unlike compressive or inflammatory myelopathies, HIV-VM typically shows non-enhancing lesions on MRI and lacks significant CSF pleocytosis. Up\u2010to\u2010date evidence emphasizes its role as a complication in patients with advanced HIV infection who often have a low CD4 count. Patients typically present with slowly progressive, symmetric spastic paraparesis, gait abnormalities, and sometimes sensory deficits. The absence of pain and rapid progression helps differentiate HIV-VM from acute infectious myelitis or compressive lesions. Knowledge of a patient\u2019s HIV status and advanced disease is key. Diagnosis is primarily by exclusion. Differential diagnoses include: vitamin B12 deficiency (which causes subacute combined degeneration with lab abnormalities), HTLV-1 associated myelopathy (requiring serologic confirmation), opportunistic infections like CMV myelitis (which typically have an acute/subacute onset and CSF abnormalities), and compressive etiologies (where MRI reveals structural lesions). A comprehensive workup including MRI of the spine, CSF analysis, and relevant laboratory tests is critical. The primary treatment is optimization of antiretroviral therapy (ART) to control HIV replication, which may slow progression. There is no specific curative therapy. Supportive measures such as physical therapy are utilized. In pregnancy or lactation, ART regimens are carefully selected to ensure fetal safety while maintaining maternal efficacy, following current HIV treatment guidelines in pregnancy. The question\u2019s option analysis highlights that common differentials (e.g., vitamin B12 deficiency, HTLV-1 myelopathy, CMV myelitis, compressive myelopathy, and multiple sclerosis) are all considered when evaluating an HIV patient with myelopathy. Because none of the provided options capture the diagnosis of HIV-VM without excluding other causes, the correct answer should be \u2018None.\u2019 The marked answer \u2018A\u2019 is incorrect given this reasoning. 1. HIV-VM is a diagnosis of exclusion in an HIV-positive patient with chronic progressive spastic paraparesis. 2. MRI usually shows non-enhancing white matter changes without evidence of a compressive lesion. 3. Improvement primarily relies on effective antiretroviral therapy. Recent studies emphasize the importance of early and sustained ART in reducing the incidence and progression of HIV-associated neurologic complications, including vacuolar myelopathy. Current guidelines suggest routine neurological evaluation in advanced HIV, and ongoing research is exploring neuroprotective adjunct therapies.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "What is most common artery affected in TB vasculopathy?",
    "option_a": "Middle cerebral artery",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Tuberculous (TB) vasculopathy is a complication of TB meningitis in which inflammatory exudates lead to vasculitis. The middle cerebral artery (MCA), particularly its perforating branches, is commonly involved due to its anatomical proximity to the basal exudates. In TB meningitis, inflammatory exudates collect in the basal cisterns and encase the cerebral vessels, leading to vascular inflammation, necrotizing arteritis, and subsequent narrowing or occlusion. The involvement of the lenticulostriate branches (perforators of the MCA) explains the high incidence of infarctions in the basal ganglia region. This vasculopathy often manifests as strokes in a younger population, with infarcts predominantly in the deep structures of the brain. Patients may present with focal neurological deficits, altered consciousness, or signs typical of meningitis. Early recognition is essential for preventing irreversible neurological damage. Diagnosis involves neuroimaging (MRI with diffusion-weighted imaging) which may reveal infarctions in the basal ganglia. Differential diagnoses include atherosclerotic stroke, other causes of infectious vasculitis (such as viral or bacterial meningitis), and autoimmune vasculitides. CSF analysis with TB cultures and PCR may also support the diagnosis. Management includes aggressive antituberculous therapy (ATT) with a combination of first-line TB drugs (such as isoniazid, rifampicin, pyrazinamide, and ethambutol) along with adjunctive corticosteroids to reduce inflammatory exudates. In patients with stroke, supportive care is provided. In pregnant or lactating women, first-line TB medications are considered safe and are recommended with appropriate monitoring. Option A, \u2018Middle cerebral artery\u2019, is correct because the inflammatory exudates in TB meningitis most commonly involve the perforating branches of the MCA. Other options might incorrectly suggest involvement of vessels less commonly affected in TB vasculopathy. 1. TB meningitis often leads to vasculitis affecting the perforating branches of the MCA. 2. Early antituberculous therapy and adjunct corticosteroids are key in managing TB meningitis complications. 3. Neuroimaging plays a crucial role in diagnosing TB vasculopathy. Recent guidelines and studies underscore the benefit of early and combined therapy (ATT plus corticosteroids) in improving outcomes in TB meningitis with vasculitic complications. Ongoing research is focused on optimizing treatment regimens to reduce neurological sequelae.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "HIV patient developed meningitis, what you will give with ceftriaxone?",
    "option_a": "Ampicillin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In cases of acute bacterial meningitis, especially in individuals with immunocompromise such as HIV, it is critical to cover for Listeria monocytogenes. The combination of ceftriaxone with ampicillin provides broad-spectrum coverage, with ampicillin specifically targeting Listeria. Listeria monocytogenes has a predilection for infecting immunocompromised individuals due to impaired cell-mediated immunity. This pathogen invades the central nervous system by crossing the blood-brain barrier, leading to meningitis characterized by inflammation and neuronal injury. HIV patients or other immunocompromised individuals frequently present with atypical or severe manifestations of bacterial meningitis. Typical signs include fever, headache, neck stiffness, and altered mental status. Given the risk for Listeria, particularly in these populations, appropriate empiric therapy is crucial. Diagnosis is based on clinical presentation and CSF analysis, which often shows a combination of neutrophilic pleocytosis, elevated protein, and low glucose. Culture and PCR can help identify the causative organism. Differential diagnoses include viral meningitis, tuberculous meningitis, and fungal meningitis. For bacterial meningitis in immunocompromised patients, current guidelines recommend initiating empirical therapy with a third-generation cephalosporin (e.g., ceftriaxone) plus ampicillin to cover Listeria. Dexamethasone can also be considered in cases suspected to be due to Streptococcus pneumoniae. In pregnant or lactating women, both ceftriaxone and ampicillin are considered safe and remain first-line agents under current recommendations. Option A (\u2018Ampicillin\u2019) is correctly marked because it provides essential coverage for Listeria monocytogenes, which is particularly important in HIV patients. With ceftriaxone alone, Listeria would not be covered, making the combination critical. 1. Always add ampicillin to cover Listeria in immunocompromised patients with suspected bacterial meningitis. 2. Combined therapy is crucial for effective empiric coverage. 3. Early initiation of appropriate antimicrobials significantly improves outcomes in meningitis. Recent updates by the Infectious Diseases Society of America (IDSA) continue to advocate for empirical coverage of Listeria in at-risk populations (those >50 years, neonates, pregnant women, and immunocompromised patients including those with HIV), reinforcing the standard use of ampicillin in combination with ceftriaxone.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "MRI - case CJD - (cortical ribbon)",
    "option_a": "nalysis provided indicates that none of the listed answer choices correctly identify the imaging hallmark of CJD (i.e., the cortical ribbon sign). The marked answer \u2018C\u2019 is therefore incorrect. The intended correct answer should be 'None' as none of the provided options accurately represent this imaging feature.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuro-infectious",
    "explanation": "Creutzfeldt-Jakob Disease (CJD) is a prion disease that presents as a rapidly progressive dementia with myoclonus and other neurological deficits. One of the characteristic imaging findings in sporadic CJD is the \u2018cortical ribbon sign,\u2019 which refers to hyperintensity along the cerebral cortex on DWI and FLAIR MRI sequences. CJD is caused by misfolded prion proteins leading to neuronal loss, spongiform changes, and gliosis. These pathological changes result in restricted diffusion on MRI that appears as a hyperintense signal along the cortical ribbon. The involvement of the basal ganglia can also be seen but the cortical changes are particularly diagnostic. Clinically, patients with CJD exhibit rapidly progressive dementia, ataxia, and myoclonus. The cortical ribbon sign correlates with the areas of brain involvement, and its recognition is critical for differentiating CJD from other causes of rapidly progressive dementia such as autoimmune encephalitis or viral encephalopathies. The diagnosis of CJD is supported by MRI findings, EEG changes (periodic sharp wave complexes), and CSF markers such as 14-3-3 protein, though definitive diagnosis often requires neuropathological confirmation. Differential diagnoses include other rapidly progressive dementias like Alzheimer\u2019s disease, vascular dementia, and autoimmune encephalitis. There is currently no curative treatment for CJD; management is primarily supportive. This includes palliative care, symptom control, and counseling for families. In the context of pregnancy or lactation, given the uniformly fatal outcome and lack of effective treatment, management focuses on supportive care and ethical decision-making. The option analysis provided indicates that none of the listed answer choices correctly identify the imaging hallmark of CJD (i.e., the cortical ribbon sign). The marked answer \u2018C\u2019 is therefore incorrect. The intended correct answer should be 'None' as none of the provided options accurately represent this imaging feature. 1. The cortical ribbon sign on DWI/FLAIR MRI is a hallmark of sporadic CJD. 2. CJD presents with rapidly progressive dementia and neurological decline. 3. Definitive diagnosis remains challenging and is largely based on clinical, radiological, and CSF findings. Current research and updated diagnostic criteria continue to support the use of MRI, especially DWI sequences, as a critical tool in the diagnosis of CJD. There is ongoing research into biomarkers and potential therapeutic targets, though effective treatment remains elusive.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with meningitis, with +ve titer for Brucella, treatment:",
    "option_a": "(Amoxicillin) is ineffective because of its limited intracellular activity and poor CNS penetration. Option b (Vancomycin) is directed at gram",
    "option_b": "",
    "option_c": "(Doxycycline",
    "option_d": "(Rifampin) may be useful as part of combination therapy but is inadequate if used alone because of the potential rapid emergence of resistance.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurobrucellosis is a challenging form of brucellosis involving the central nervous system. Brucella species are intracellular gram\u2010negative bacteria that can cause meningitis, and effective treatment requires antibiotics that not only have bacteriostatic or bactericidal effects against Brucella but also can penetrate the blood\u2013brain barrier and reach intracellular compartments. Brucella bacteria invade and survive within phagocytic cells, establishing a chronic infection. In neurobrucellosis, the bacteria enter the CNS causing inflammation of the meninges or parenchymal brain involvement. Their intracellular lifestyle makes it necessary to use drugs (like doxycycline) that have good intracellular penetration combined with a bactericidal agent (such as ceftriaxone) that also attains high levels in the CNS. Patients typically present with symptoms of meningitis such as headache, fever, neck stiffness, and sometimes focal neurological deficits. A positive Brucella serology (titer) supports the diagnosis, especially in endemic areas, and mandates treatment with a regimen that effectively penetrates both intracellular compartments and the CNS. Diagnosis is based on a combination of clinical signs, a positive serological test (e.g., standard agglutination test), and sometimes CSF analysis. Differential diagnoses include tuberculous meningitis, viral meningitis, and other bacterial etiologies. Culture results are often slow and may be negative, hence treatment is often initiated based on clinical suspicion and serology. According to current guidelines, the first-line treatment for neurobrucellosis typically includes a multidrug regimen. The combination of doxycycline (for its excellent intracellular penetration) and ceftriaxone (for its bactericidal effect and excellent CNS penetration) is recommended. Alternatives or additions may include rifampin; however, rifampin should not be used as monotherapy due to risk of resistance. Pregnancy and lactation considerations are critical: doxycycline is contraindicated during pregnancy and early lactation. In pregnant patients with neurobrucellosis, alternative regimens such as trimethoprim-sulfamethoxazole (after the first trimester) or other safe agents may be considered while balancing maternal benefits and fetal risks. Option a (Amoxicillin) is ineffective because of its limited intracellular activity and poor CNS penetration. Option b (Vancomycin) is directed at gram-positive organisms and does not address intracellular Brucella. Option c (Doxycycline-Ceftriaxone) combines effective intracellular bacteriostatic action with CNS-penetrating bactericidal therapy, making it the recommended regimen. Option d (Rifampin) may be useful as part of combination therapy but is inadequate if used alone because of the potential rapid emergence of resistance. 1. Always choose agents with both intracellular activity and proven CNS penetration when treating neurobrucellosis. 2. Multi-drug regimens are essential to prevent relapse and resistance. 3. In pregnant patients, doxycycline is contraindicated, and alternative regimens should be considered. Recent studies and systematic reviews support the use of doxycycline combined with ceftriaxone for neurobrucellosis, as these agents have proven CNS penetration and intracellular activity. Updated guidelines from international infectious disease societies emphasize combination therapy, particularly in patients with CNS involvement, while also highlighting adjustments needed during pregnancy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Oculomasticatory myorhythmia, Dx",
    "option_a": "(CSF analysis) and option b (MRI) offer supportive but nonspecific findings and cannot provide a definitive diagnosis. Option c (Jejunal biopsy) is correct because it directly demonstrates the presence of T. whipplei through PAS staining and PCR, confirming the diagnosis. This test remains the gold standard.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "Oculomasticatory myorhythmia (OMM) is a distinctive and nearly pathognomonic clinical sign associated with central nervous system (CNS) involvement in Whipple's disease. Recognizing this movement disorder helps target the appropriate diagnostic evaluation. Whipple's disease is caused by the bacterium Tropheryma whipplei. The organism has a predilection for the gastrointestinal tract but can disseminate to extraintestinal sites, notably involving the CNS. The abnormal, rhythmic movements of ocular and masticatory muscles (OMM) result from specific brainstem and diencephalic lesions. Patients with Whipple's disease may present with systemic symptoms such as weight loss, arthralgias, and gastrointestinal disturbances, along with neurological signs including OMM, cognitive changes, and ataxia. The presence of OMM strongly suggests CNS involvement. While cerebrospinal fluid (CSF) analysis and MRI can support the diagnosis by showing inflammatory or nonspecific changes, the gold standard for confirming Whipple's disease is a jejunal biopsy. Histopathologic examination with periodic acid\u2013Schiff (PAS) staining, along with PCR for T. whipplei, provides definitive evidence. The first-line treatment for Whipple's disease involves prolonged antibiotic therapy. Typically, initial management uses intravenous ceftriaxone to achieve high CNS concentrations followed by an extended course (often 1\u20132 years) of oral trimethoprim-sulfamethoxazole (TMP-SMX). In pregnancy, TMP-SMX is generally contraindicated, especially in the first trimester, so alternative regimens (e.g., extended use of safe cephalosporins or other agents with CNS penetration) should be considered while managing the risks and benefits. Option a (CSF analysis) and option b (MRI) offer supportive but nonspecific findings and cannot provide a definitive diagnosis. Option c (Jejunal biopsy) is correct because it directly demonstrates the presence of T. whipplei through PAS staining and PCR, confirming the diagnosis. This test remains the gold standard. 1. Oculomasticatory myorhythmia is highly specific for CNS Whipple's disease. 2. Jejunal biopsy with PAS staining is the diagnostic gold standard. 3. A high index of suspicion is needed in patients with systemic symptoms and neurological signs. Recent literature reinforces the role of jejunal biopsy combined with PCR as the definitive diagnostic method for Whipple's disease. Ongoing research aims to improve earlier detection and tailor antibiotic therapy, particularly in patients with neurological involvement.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "HIV, with deteriorated LOC, CT: enhancing mass. What is your next step?",
    "option_a": "(Biopsy) is correct as it provides a definitive diagnosis, preventing delays in appropriate management. Option b (Empirical treatment with pyrimethamine and sulfadiazine) is not advisable in a deteriorating patient because it might delay diagnosis and is appropriate primarily when the clinical picture is typical for toxoplasmosis in a stable patient.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV-positive patients, the appearance of an enhancing intracranial mass on CT, especially in the context of a deteriorating level of consciousness, raises a critical diagnostic challenge. Differentiating between opportunistic infections such as toxoplasmosis and primary CNS lymphoma (PCNSL) is essential for appropriate management. In immunocompromised patients, toxoplasmosis (caused by Toxoplasma gondii) often leads to multiple ring-enhancing lesions, whereas PCNSL usually presents as a solitary or few enhancing masses. The underlying immune deficiency in HIV facilitates these opportunistic processes with distinct pathological features that require tissue diagnosis for proper identification. A rapidly deteriorating level of consciousness in an HIV patient with an intracranial mass necessitates prompt diagnostic clarification. Imaging studies may suggest certain possibilities, but they lack definitive specificity. Relying solely on clinical and radiological findings may lead to misdiagnosis and inappropriate therapy. The immediate next step is to obtain a biopsy of the lesion. This allows histopathological examination and immunohistochemical studies to definitively differentiate between CNS lymphoma, toxoplasmosis, and other potential lesions. Differential diagnoses include cerebral toxoplasmosis, PCNSL, tuberculoma, and fungal infections. Definitive management depends on the biopsy results: if the lesion is due to toxoplasmosis, the standard treatment involves pyrimethamine plus sulfadiazine and leucovorin, whereas PCNSL is treated with high-dose methotrexate-based chemotherapy and possibly radiation therapy. In patients with rapid clinical deterioration, early biopsy is recommended rather than empirical treatment. In pregnant patients with HIV, the choice of therapy must consider fetal safety; many chemotherapeutic agents have teratogenic potential, making diagnostic clarity even more crucial. Option a (Biopsy) is correct as it provides a definitive diagnosis, preventing delays in appropriate management. Option b (Empirical treatment with pyrimethamine and sulfadiazine) is not advisable in a deteriorating patient because it might delay diagnosis and is appropriate primarily when the clinical picture is typical for toxoplasmosis in a stable patient. 1. In HIV patients with brain masses, always consider both infectious and neoplastic etiologies. 2. Tissue diagnosis via biopsy is critical when the clinical presentation is atypical or rapidly deteriorating. 3. Empirical therapy should be reserved for stable patients with typical findings. Current guidelines emphasize early biopsy in HIV-positive patients with atypical or rapidly worsening CNS lesions. Recent studies show that relying on empirical treatment without histological confirmation can lead to suboptimal outcomes, and precision medicine approaches are increasingly important in this population.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Schistosomiasis patient with LL weakness & high eosinophils in CBC, ttt",
    "option_a": "Praziquantel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Schistosomiasis is a parasitic infection caused by trematode flatworms of the genus Schistosoma. When the infection involves the nervous system, particularly the spinal cord, it can lead to lower limb weakness. Effective management is based on using an antiparasitic agent that targets the parasite throughout its lifecycle. The pathology in neuroschistosomiasis involves the deposition of Schistosoma eggs in the spinal cord tissue, which incites a local granulomatous inflammatory reaction. This immune response can cause edema, demyelination, and eventual fibrosis, resulting in neurologic deficits such as weakness in the lower limbs. Patients present with lower limb weakness, often accompanied by sensory disturbances and a history suggestive of schistosomal exposure. A high eosinophil count on CBC supports the diagnosis of a parasitic infection, including schistosomiasis. Diagnosis is typically confirmed by identifying Schistosoma eggs in stool or urine, serologic tests, or characteristic imaging findings. The differential diagnosis includes other causes of myelopathy such as transverse myelitis, multiple sclerosis, or other parasitic infections, which can be differentiated by epidemiological data, laboratory investigations (eosinophilia, serology), and imaging. Praziquantel is the first-line treatment for all forms of schistosomiasis due to its efficacy against the adult worms. In cases with spinal cord involvement, some clinicians may also use adjunctive corticosteroids to mitigate inflammatory responses. Concerning pregnancy and lactation, Praziquantel is generally considered safe (classified as Pregnancy Category B), though its use in the first trimester should be weighed against the potential risks of untreated schistosomiasis. Option A (Praziquantel) is the correct treatment option as it is the recommended first-line therapeutic agent for schistosomiasis. The other options (not provided here) likely do not offer the same targeted anti-parasitic efficacy or have less favorable evidence in treating neuroschistosomiasis. 1. Eosinophilia in a patient with neurological deficits should raise suspicion for parasitic infections. 2. Praziquantel remains the cornerstone of schistosomiasis treatment. 3. Early treatment is essential to prevent irreversible neurological damage. Recent updates in WHO guidelines and multiple clinical studies continue to support Praziquantel as the treatment of choice for schistosomiasis, including cases with neural involvement. Ongoing research is assessing the role of adjunctive therapies to further improve neurological outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "In case of cavernous mucormycosis, which is true",
    "option_a": "is correct because mucormycosis in the cavernous sinus primarily spreads through direct invasion from contiguous structures. Option b is incorrect because mucormycosis is known to be rapidly progressive, not slowly progressive. Option c is incorrect since hematogenous spread is rare. Option d is incorrect because mucormycosis is an uncommon opportunistic infection.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "Cavernous mucormycosis represents an aggressive fungal infection that typically invades from the paranasal sinuses into the cavernous sinus via direct contiguous spread. The key principle is the angioinvasive nature of mucormycosis, which allows rapid invasion through local anatomical structures. Mucormycosis is caused by fungi of the order Mucorales. In cavernous sinus involvement, the fungus invades vascular structures leading to thrombosis, infarction, and tissue necrosis. The infection spreads directly from the nasal cavity and paranasal sinuses, exploiting bony defects and vascular channels rather than disseminating hematogenously. Patients, often immunosuppressed (e.g., diabetic ketoacidosis or neutropenic), may present with facial pain, orbital swelling, ophthalmoplegia, and signs of cavernous sinus syndrome. The rapid progression is due to the angioinvasion which can result in infarction of cranial nerves and adjacent brain tissues. Diagnosis involves imaging studies such as CT or MRI to evaluate the extent of sinus and orbital involvement and evidence of cavernous sinus thrombosis. Differential diagnoses include bacterial cavernous sinus thrombosis, neoplasms, or other fungal infections. Tissue biopsy with fungal stains and culture confirm the diagnosis. The cornerstone of management is rapid initiation of high-dose intravenous liposomal Amphotericin B combined with urgent surgical debridement. Second-line agents like posaconazole or isavuconazole may be used as adjuncts. In pregnancy and lactation, liposomal Amphotericin B is preferred due to its safety profile. Glycemic control and reversal of underlying immunocompromised states are also essential. Option a is correct because mucormycosis in the cavernous sinus primarily spreads through direct invasion from contiguous structures. Option b is incorrect because mucormycosis is known to be rapidly progressive, not slowly progressive. Option c is incorrect since hematogenous spread is rare. Option d is incorrect because mucormycosis is an uncommon opportunistic infection. 1. Mucormycosis is a rapidly progressive, life-threatening fungal infection requiring early recognition and treatment. 2. Direct invasion from the paranasal sinuses is the hallmark of cavernous mucormycosis. 3. Aggressive management with both antifungal therapy and surgical debridement is critical. Recent guidelines and clinical studies emphasize early diagnosis by imaging and tissue biopsy, with immediate initiation of liposomal Amphotericin B as the standard of care. Current research is focused on optimizing antifungal regimens and the role of adjunctive therapies in immunocompromised patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of sinusitis, Hx of headache, proptosis, & ocular dysmotility.",
    "option_a": "(Metronidazole) is incorrect because it lacks antifungal activity and is used for anaerobic bacterial infections. Option b (Fluconazole) is inappropriate since it is not active against molds. Option c (Amphotericin) is correct as it is the first",
    "option_b": "",
    "option_c": "",
    "option_d": "(Flucytosine) is incorrect because it is primarily used for cryptococcal infections and has no role in treating invasive mold infections.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "In cases of invasive fungal sinusitis with orbital involvement (manifested by headache, proptosis, and ocular dysmotility), the primary therapeutic strategy is targeting the invasive mold with an effective antifungal agent. Invasive fungal sinusitis such as mucormycosis or aspergillosis typically exhibits rapid tissue invasion and angioinvasion. This leads to necrosis and extension into the orbit and cavernous sinus, which explains the ocular symptoms including proptosis and ocular dysmotility. Patients present with acute sinusitis symptoms along with orbital signs. The constellation of headache, proptosis, and impaired ocular movement points towards orbital or cavernous sinus involvement secondary to the invasive nature of the fungal infection. Imaging modalities like CT and MRI help in assessing the extent of sinus, orbital, and intracranial involvement. Differential diagnoses include bacterial orbital cellulitis and non-infectious inflammatory conditions. Microbiological studies and tissue biopsy are definitive for fungal etiology. First-line management is high-dose intravenous liposomal Amphotericin B, given its broad-spectrum fungicidal activity and good tissue penetration. Surgical debridement is often required as an adjunct. For patients who are pregnant or lactating, liposomal Amphotericin B is considered the treatment of choice due to its relatively safe profile during pregnancy. Option a (Metronidazole) is incorrect because it lacks antifungal activity and is used for anaerobic bacterial infections. Option b (Fluconazole) is inappropriate since it is not active against molds. Option c (Amphotericin) is correct as it is the first-line treatment for invasive fungal infections like mucormycosis. Option d (Flucytosine) is incorrect because it is primarily used for cryptococcal infections and has no role in treating invasive mold infections. 1. Invasive fungal sinusitis is a medical emergency requiring rapid intervention. 2. Orbital involvement (proptosis and ocular dysmotility) strongly suggests an aggressive infectious process. 3. Liposomal Amphotericin B is the gold standard due to its efficacy and safety in special populations such as pregnant women. Recent reviews and guidelines reinforce the early use of liposomal Amphotericin B and prompt surgical debridement in invasive fungal sinusitis. Ongoing research is focused on newer antifungal agents and combination therapies to improve outcomes in high-risk populations.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "About cryptococcus? -Appear as gelatinous pseudocysts",
    "option_a": "(Appear as gelatinous pseudocysts) is correct because this characteristic appearance on imaging and histopathology distinguishes cryptococcal CNS infection from other infections. Other options that might suggest the formation of true cysts or bacterial abscesses are incorrect.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Cryptococcal infection primarily affects the CNS, especially in immunocompromised hosts, and is classically associated with distinctive pathological findings, such as the formation of gelatinous pseudocysts. Cryptococcus neoformans, an encapsulated yeast, invades the central nervous system where it accumulates in perivascular spaces. The mucopolysaccharide capsule leads to a gelatinous consistency in these pseudocysts, which is a hallmark finding on both imaging and histopathology. In cryptococcal meningitis, patients may present with headache, altered mental status, and cranial nerve deficits. On neuroimaging, dilated Virchow-Robin spaces and gelatinous pseudocysts are often seen, correlating with the pathological deposition of the organism and its capsule. Diagnosis is confirmed with CSF analysis, including India ink staining, cryptococcal antigen testing, and culture. Differential diagnoses include tuberculous meningitis, other fungal infections, and encephalitis; however, the presence of gelatinous pseudocysts strongly favors cryptococcosis. The standard treatment for cryptococcal meningitis involves an induction phase with Amphotericin B (preferably liposomal) combined with flucytosine, followed by a consolidation and maintenance phase with fluconazole. In pregnant women, Amphotericin B is the treatment of choice due to its safety profile, while flucytosine is typically avoided due to potential teratogenicity. Lactating patients are managed similarly with careful monitoring. Option A (Appear as gelatinous pseudocysts) is correct because this characteristic appearance on imaging and histopathology distinguishes cryptococcal CNS infection from other infections. Other options that might suggest the formation of true cysts or bacterial abscesses are incorrect. 1. Always consider cryptococcal meningitis in immunocompromised patients presenting with meningeal signs. 2. Gelatinous pseudocysts in the perivascular spaces are a key radiologic and histologic feature. 3. Early diagnosis and treatment significantly impact outcomes. Current guidelines emphasize early initiation of combination antifungal therapy and highlight the importance of intracranial pressure management. Research continues into optimizing induction regimens and reducing long-term neurological complications.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Infection with Retinal whitening with orang spot",
    "option_a": "(Bartonella) is correct because it is the most common cause of neuroretinitis presenting with retinal whitening and a macular star/orange spot. Option b (TB) is incorrect because tuberculous retinal involvement typically presents with choroidal granulomas rather than a macular star. Option c (CMV) is incorrect as CMV retinitis in immunocompromised individuals shows a 'pizza pie' hemorrhagic pattern. Option d (Toxoplasmosis) is incorrect because toxoplasmosis commonly manifests as a focal necrotizing retinochoroiditis with distinct scar formation from previous outbreaks.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neuroretinitis is an inflammatory condition affecting the optic nerve and retina. Certain infectious agents, notably Bartonella henselae, cause a distinctive retinal appearance characterized by retinal whitening and a macular star (orange spot), which result from lipid-rich exudates. Bartonella henselae, the bacterium responsible for cat scratch disease, can lead to inflammation of the optic nerve and peripapillary retina. The leakage of lipids from the inflamed retinal vessels forms a star-shaped exudate at the macula. This process explains the characteristic retinal whitening and the 'orange spot' observed on fundoscopic examination. Patients often present with visual disturbances, decreased visual acuity, and pain associated with the affected eye. A history of cat exposure is frequently present. The constellation of findings of optic disc edema and a macular star is highly suggestive of Bartonella-induced neuroretinitis. Diagnosis is typically clinical, supported by serologic testing for Bartonella henselae. Differential diagnoses include tuberculous uveitis (which generally shows choroidal tubercles), CMV retinitis (characterized by hemorrhagic retinal necrosis in immunocompromised patients), and toxoplasmosis (which presents with focal retinochoroiditis). The first-line treatment for Bartonella neuroretinitis is an appropriate antibiotic regimen such as azithromycin or doxycycline. In pregnant or lactating patients, azithromycin is preferred due to its safety profile. Corticosteroids may be considered in select cases to reduce inflammation, but their use must be weighed against potential risks. Option a (Bartonella) is correct because it is the most common cause of neuroretinitis presenting with retinal whitening and a macular star/orange spot. Option b (TB) is incorrect because tuberculous retinal involvement typically presents with choroidal granulomas rather than a macular star. Option c (CMV) is incorrect as CMV retinitis in immunocompromised individuals shows a 'pizza pie' hemorrhagic pattern. Option d (Toxoplasmosis) is incorrect because toxoplasmosis commonly manifests as a focal necrotizing retinochoroiditis with distinct scar formation from previous outbreaks. 1. A history of cat exposure can be a critical clue for Bartonella-related neuroretinitis. 2. The presence of a macular star is highly suggestive of neuroretinitis, particularly due to Bartonella. 3. Early diagnosis and tailored antibiotic therapy can lead to favorable visual outcomes. Recent studies support the use of azithromycin as first-line therapy in neuroretinitis secondary to Bartonella henselae, highlighting its efficacy and safety profile, especially in special populations such as pregnant and lactating women. Current guidelines emphasize prompt recognition and treatment to prevent permanent visual impairment.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Commonest organism in meningitis Pneumonia",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Strep",
    "subspecialty": "Neuro-infectious",
    "explanation": "Bacterial meningitis in adults is most commonly caused by Streptococcus pneumoniae. This organism is responsible for a large proportion of community\u2010acquired cases due to its virulence factors and its prevalence in the nasopharynx. Streptococcus pneumoniae has a polysaccharide capsule that helps it evade immune detection. Once it breaches the blood\u2013brain barrier, an intense inflammatory response is triggered in the subarachnoid space, leading to the classic signs of meningitis. The release of bacterial toxins and subsequent immune-mediated injury result in increased intracranial pressure and neurological symptoms. Patients typically present with fever, headache, neck stiffness, altered mental status, and sometimes seizures. The severity of inflammation can lead to complications such as hearing loss, brain edema, or infarction. Pneumococcal pneumonia is also common, and the bacteria's ability to cause both pneumonia and meningitis underscores its clinical significance. Diagnosis is established through lumbar puncture with CSF analysis (elevated white cell count with neutrophilic predominance, low glucose, high protein) and Gram stain/culture. Differential diagnoses include meningococcal meningitis (Neisseria meningitidis), Listeria monocytogenes (in neonates, elderly, and immunocompromised), and Haemophilus influenzae type b (rare in adults due to vaccination). First-line treatment according to current guidelines involves high-dose intravenous ceftriaxone often combined with vancomycin to cover penicillin-resistant strains. Adjunctive dexamethasone is recommended to reduce neurological complications. In pregnant or lactating patients, ceftriaxone is considered safe (Pregnancy Category B), and dexamethasone is used when the benefit outweighs any potential risk. Treatment adjustments are made based on culture results and patient status. The provided option, Streptococcus pneumoniae (marked as 'Strep'), is correct. Alternatives such as Neisseria meningitidis, Haemophilus influenzae, or Listeria monocytogenes are less common in the adult community-acquired setting, each having distinct epidemiological profiles. 1. Always consider patient age and immune status \u2013 pneumococcal meningitis is predominant in adults. 2. Early administration of dexamethasone, ideally before or with the first dose of antibiotics, can improve outcomes. 3. Vaccination (pneumococcal conjugate and polysaccharide vaccines) is a key preventive measure. Recent clinical guidelines by the Infectious Diseases Society of America (IDSA) and updates based on emerging antibiotic resistance patterns continue to support the use of ceftriaxone (plus vancomycin in areas with high penicillin resistance) and adjunctive corticosteroid therapy as the standard of care for pneumococcal meningitis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "CJD case for organ donation",
    "option_a": "",
    "option_b": "",
    "option_c": ", 'Do not take any organ', is correct. Options suggesting selective organ donation (like harvesting kidney or liver) or using a negative brain biopsy to justify donation are incorrect due to the systemic nature of prion infectivity and the limitations of diagnostic sensitivity.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "Creutzfeldt-Jakob Disease (CJD) is a prion disease, which is unique among neurodegenerative conditions due to its transmissibility via prion proteins. In the context of organ donation, the potential for iatrogenic transmission makes precautions paramount. CJD is caused by misfolded prion proteins that induce a cascade of misfolding in normal proteins, leading to a spongiform degeneration of brain tissue. Prions are resistant to standard sterilization procedures and can be present in tissues beyond the central nervous system, thereby posing a risk of transmission if transplanted. Clinically, CJD presents as a rapidly progressive dementia with myoclonus and neurological deficits. Because the disease is invariably fatal and prions spread through neural tissue, iatrogenic transmission is a critical concern in medical procedures, including organ transplantations. The diagnosis of CJD is supported by clinical findings, EEG changes (periodic sharp wave complexes), CSF markers (elevated 14-3-3 protein), and MRI brain findings (high signal intensity in the basal ganglia or cortical ribboning on DWI). Brain biopsy remains controversial due to its limited sensitivity and risk of transmission. There is no definitive treatment for CJD; management is supportive. Importantly, current international guidelines strictly prohibit organ donation from patients with confirmed or suspected CJD to avoid iatrogenic spread of the prion. In these cases, every organ is potentially contaminated, and the risk far outweighs any benefit of transplantation. Option c, 'Do not take any organ', is correct. Options suggesting selective organ donation (like harvesting kidney or liver) or using a negative brain biopsy to justify donation are incorrect due to the systemic nature of prion infectivity and the limitations of diagnostic sensitivity. 1. CJD is nearly uniformly fatal with no effective therapies. 2. Prions are resistant to standard sterilization making surgical procedures and transplants particularly risky. 3. Always rule out suspected prion disease in potential organ donors to prevent iatrogenic transmission. Recent guidelines from the World Health Organization (WHO) and other international agencies emphasize an absolute contraindication for organ donation in any case of suspected or confirmed CJD. Research continues into improved diagnostic methodologies, but no method yet offers a safe threshold for organ procurement.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Primary amoebic meningoencephalitis (PAM)",
    "option_a": "Self-limited",
    "option_b": "1ry root of infection is through cribriform plate",
    "option_c": "Very common",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Primary amoebic meningoencephalitis (PAM) is a rare but almost always fatal infection of the brain caused by the free-living amoeba Naegleria fowleri. The organism typically gains access to the central nervous system through the nasal passages. Naegleria fowleri enters the central nervous system by invading through the nasal mucosa and then traveling along the olfactory nerve fibers, penetrating the cribriform plate. This invasion results in widespread necrosis and an acute, fulminant inflammatory response in the brain. The infection usually presents with sudden onset of headache, fever, nausea, vomiting, and later, rapid deterioration in mental status leading to coma and death within days. The rapid clinical course is a hallmark of PAM. Diagnosis can be assisted by CSF analysis (which may show elevated white cell count with neutrophilic predominance) and direct visualization of the amoeba on a wet mount of the CSF. Differential diagnoses include bacterial meningitis, viral encephalitis, and other parasitic CNS infections, but the rapid, fulminant course and history of freshwater exposure are distinguishing factors. Management is very challenging due to the rapid progression of the disease. Current treatment recommendations include a combination of intravenous and intrathecal antifungals and antimicrobials such as amphotericin B, along with newer agents like miltefosine, although success rates remain low. In pregnant or lactating patients, treatment is similarly complex; however, due to the rarity of the condition, there are no specialized guidelines, and therapy is largely based on case reports and expert opinion. Option B, indicating that the primary route of infection is via the cribriform plate, is correct. Option A (suggesting a self-limited course) is incorrect as PAM is rapidly fatal. Option C (stating it is very common) is also incorrect given its rarity. 1. Naegleria fowleri infection is almost universally fatal, with very few survivors reported. 2. History of recent freshwater exposure (e.g., swimming in lakes) is critical for diagnosis. 3. Early recognition is essential, though treatment outcomes remain poor. Recent literature emphasizes the critical nature of early diagnosis and aggressive multi-drug regimens, though survival remains extremely limited. Research into novel therapeutic agents, such as combination therapies including miltefosine, is ongoing.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Prophylaxis in case of contact with pt came with meningitis from Al Haj (rifampin was not mentioned)",
    "option_a": "",
    "option_b": "",
    "option_c": "(ciprofloxacin) is correct in the context of prophylaxis for adult contacts when rifampin is not used; it effectively eradicates pharyngeal carriage. Option D (ceftriaxone) is also correct, particularly for pregnant or lactating contacts and children, but given the question likely requires a single best answer and the marked answer is ciprofloxacin, option C is acceptable. Options A (vancomycin) and B (amoxicillin) are not effective in eradicating meningococcal carriage.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "Contacts of patients with meningococcal meningitis are at increased risk for developing the disease, and prophylactic antibiotics are used to eliminate nasopharyngeal carriage of Neisseria meningitidis. The typical primary prophylaxis is rifampin, but when it is not mentioned or contraindicated, alternatives are necessary. Neisseria meningitidis colonizes the nasopharynx and can invade the bloodstream to cause meningitis. The goal of prophylaxis is to eradicate this carriage before invasive disease develops among close contacts. Close contacts, especially in settings of outbreaks or close living conditions such as dormitories or pilgrimages (like Al Haj), are at risk. Prompt prophylaxis can prevent the spread of a potentially lethal infection. While prophylaxis does not require a diagnostic work-up, identifying meningococcal disease in index cases relies on CSF analysis, Gram stain, and culture. Differential considerations include other causes of bacterial meningitis, but the prophylactic intervention is specifically aimed at meningococcal infections. First-line prophylaxis is usually rifampin; however, when it is not indicated or available, alternatives include a single oral dose of ciprofloxacin (typically for non-pregnant adults) or a single intramuscular dose of ceftriaxone. In pregnant or lactating patients, ceftriaxone is preferred because ciprofloxacin is generally avoided during pregnancy due to potential cartilage toxicity concerns, even though it may sometimes be used in non-pregnant adults. The CDC and IDSA strongly endorse these guidelines. Option C (ciprofloxacin) is correct in the context of prophylaxis for adult contacts when rifampin is not used; it effectively eradicates pharyngeal carriage. Option D (ceftriaxone) is also correct, particularly for pregnant or lactating contacts and children, but given the question likely requires a single best answer and the marked answer is ciprofloxacin, option C is acceptable. Options A (vancomycin) and B (amoxicillin) are not effective in eradicating meningococcal carriage. 1. Prophylactic regimens for meningococcal exposure must be chosen based on the patient\u2019s age, pregnancy status, and contraindications. 2. A single dose of ciprofloxacin is effective in many adults, while ceftriaxone is the alternative for pregnant women and children. 3. Rapid administration of prophylactic antibiotics can prevent secondary cases in close contacts. Current CDC and IDSA guidelines support the use of ciprofloxacin for meningococcal prophylaxis in non-pregnant adults and ceftriaxone for pregnant or pediatric patients. Research continues on optimizing prophylactic strategies during outbreaks such as those encountered in mass gatherings (e.g., Hajj).",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]